Literature DB >> 33546693

Prognostic value of eight immune gene signatures in pancreatic cancer patients.

Wenting Wang1, Zhijian Xu1, Ning Wang1, Ruyong Yao2, Tao Qin1, Hao Lin1, Lu Yue3.   

Abstract

BACKGROUND: Pancreatic cancer is one of the most common malignant tumors of the digestive tract, and it has a poor prognosis. Traditional methods are not effective to accurately assess the prognosis of patients with pancreatic cancer. Immunotherapy is a new promising approach for the treatment of pancreatic cancer; however, some patients do not respond well to immunotherapy, which may be related to tumor microenvironment regulation. In this study, we use gene expression database to mine important immune genes and establish a prognostic prediction model for pancreatic cancer patients. We hope to provide a feasible method to evaluate the prognosis of pancreatic cancer and provide valuable targets for pancreatic cancer immunotherapy.
RESULTS: We used univariate COX proportional hazard regression analysis, the least absolute shrinkage and selection operator, and multivariate COX regression analysis to screen 8 genes related to prognosis from the 314 immune-related genes, and used them to construct a new clinical prediction model in the TCGA pancreatic cancer cohort. Subsequently, we evaluated the prognostic value of the model. The Kaplan-Meier cumulative curve showed that patients with low risk scores survived significantly longer than patients with high risk scores. The area under the ROC curve (AUC value) of the risk score was 0.755. The univariate COX analysis showed that the risk score was significantly related to overall survival (HR 1.406, 95% CI 1.237-1.598, P < 0.001), and multivariate analysis showed that the risk score was an independent prognostic factor (HR 1.400, 95% CI 1.287-1.522, P < 0.001). Correlation analysis found that immune genes are closely related to tumor immune microenvironment.
CONCLUSIONS: Based on the TCGA-PAAD cohort, we identified immune-related markers with independent prognostic significance, validated, and analyzed their biological functions, to provide a feasible method for the prognosis of pancreatic cancer and provide potentially valuable targets for pancreatic cancer immunotherapy.

Entities:  

Year:  2021        PMID: 33546693      PMCID: PMC7863419          DOI: 10.1186/s12920-020-00868-w

Source DB:  PubMed          Journal:  BMC Med Genomics        ISSN: 1755-8794            Impact factor:   3.063


  45 in total

1.  Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.

Authors:  Ni Jiang; Guoliang Qiao; Xiaoli Wang; Michael A Morse; William R Gwin; Lei Zhou; Yuguang Song; Yanjie Zhao; Feng Chen; Xinna Zhou; Lefu Huang; Amy Hobeika; Xin Yi; Xuefeng Xia; Yanfang Guan; Jin Song; Jun Ren; H Kim Lyerly
Journal:  Clin Cancer Res       Date:  2017-06-13       Impact factor: 12.531

2.  Early detection and imaging strategies to reveal and target developing pancreatic cancer.

Authors:  Howard C Crawford; Michael B Wallace; Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2020-01-27       Impact factor: 4.512

3.  Inhibition of SHP-1 expands the repertoire of antitumor T cells available to respond to immune checkpoint blockade.

Authors:  Jeremy P Snook; Ashleigh J Soedel; H Atakan Ekiz; Ryan M O'Connell; Matthew A Williams
Journal:  Cancer Immunol Res       Date:  2020-02-19       Impact factor: 11.151

4.  Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation.

Authors:  Juan Pablo Arnoletti; Xiang Zhu; Alvin J O Almodovar; Paula P Veldhuis; Ryan Sause; Elizabeth Griffith; George Corpus; Jeffrey C C Chang; Naʼim Fanaian; Sally A Litherland
Journal:  Pancreas       Date:  2017-01       Impact factor: 3.327

5.  Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.

Authors:  Shiping Jiao; Sumit K Subudhi; Ana Aparicio; Zhongqi Ge; Baoxiang Guan; Yuji Miura; Padmanee Sharma
Journal:  Cell       Date:  2019-11-14       Impact factor: 41.582

6.  Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.

Authors:  Satyanarayana Medicherla; Lingyun Li; Jing Ying Ma; Ann M Kapoun; Nicholas J Gaspar; Yu-Wang Liu; Ruban Mangadu; Gilbert O'Young; Andrew A Protter; George F Schreiner; Darren H Wong; Linda S Higgins
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

7.  Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling.

Authors:  Erick Riquelme; Anirban Maitra; Florencia McAllister
Journal:  Cancer Discov       Date:  2018-04       Impact factor: 39.397

8.  Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells.

Authors:  Xingda Wu; Zhe Liu; Kejia Guo; Gang Ma; Shaowei Song
Journal:  J Cell Biochem       Date:  2018-10-26       Impact factor: 4.429

9.  Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer.

Authors:  Jun Zhao; Xiaofei Wen; Li Tian; Tingting Li; Chunyu Xu; Xiaoxia Wen; Marites P Melancon; Sanjay Gupta; Baozhong Shen; Weiyi Peng; Chun Li
Journal:  Nat Commun       Date:  2019-02-22       Impact factor: 14.919

10.  Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.

Authors:  Katrin Aslan; Verena Turco; Jens Blobner; Jana K Sonner; Anna Rita Liuzzi; Nicolás Gonzalo Núñez; Donatella De Feo; Philipp Kickingereder; Manuel Fischer; Ed Green; Ahmed Sadik; Mirco Friedrich; Khwab Sanghvi; Michael Kilian; Frederik Cichon; Lara Wolf; Kristine Jähne; Anna von Landenberg; Lukas Bunse; Felix Sahm; Daniel Schrimpf; Jochen Meyer; Allen Alexander; Gianluca Brugnara; Ralph Röth; Kira Pfleiderer; Beate Niesler; Andreas von Deimling; Christiane Opitz; Michael O Breckwoldt; Sabine Heiland; Martin Bendszus; Wolfgang Wick; Burkhard Becher; Michael Platten
Journal:  Nat Commun       Date:  2020-02-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.